Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0000737 (abdominal pain)
 31,184 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

A dose of 0.3 micrograms/kg body weight of ceruletide was assessed for its effect on gallbladder contraction and bile duct delineation following oral cholecystography. Nausea, vomiting, and abdominal pain sometimes occurred after ceruletide. No relationship was found after ceruletide administration between the radiologic appearances of the biliary tract and reproduction of the patients' biliary-type symptoms. Ceruletide cholecystography is regarded as an inaccurate investigation of biliary tract function.
 ...
PMID:Assessment of gallbladder function using ceruletide in oral cholecystography. 399 37

The effect of injection of a cholecystokinetic agent, Ceruletide, was compared with that of the fatty meal following a single dose of Biloptin, and Biloptin with Solubiloptin, in regard to efficiency of gall-bladder contraction, cystic and common bile duct visualisation and side effects. In terms of gall-bladder contraction and ductal delineation no advantage was found from giving Ceruletide or Solubiloptin. Gall-bladder contraction occurred more quickly after Ceruletide than after a fatty meal, with corresponding earlier duct delineation, although the gall bladder was completely emptied of contrast medium in a significant proportion of Ceruletide cases. The incidence of abdominal pain was significantly greater after Ceruletide than after a fatty meal. Because Ceruletide requires an intramuscular injection and has no significant advantage over the fatty meal in regard to gall-bladder contraction and ductal delineation, its use in cholecystography is unjustified. A morning dose of Solubiloptin following Biloptin the previous evening offers no advantage over the Biloptin and fatty meal regimen.
 ...
PMID:Gall-bladder contraction and bile duct opacification in oral cholecystography--a comparison of different methods. 634 1

Ceruletide, a decapeptide, is a potent cholecystokinetic agent with a direct spasmogenic effect on the gallbladder muscle and bile ducts in humans and animals. It was recently approved by the Food and Drug Administration for use as an adjunct in x-ray examination of the gallbladder and small bowel. The drug causes a coordinated propulsive activity from the duodenum to the ileum and segmenting activity in the colon. Because of this stimulatory effect, ceruletide is useful not only diagnostically as an aid in x-ray examination of the small bowel, but also therapeutically for treatment of postoperative ileus, intestinal atonia, and chronic fecal statis. Because of its pancreatic stimulatory action, it is useful in evaluation of exocrine pancreatic function. In therapeutic doses the adverse effects noted are mild, transient extensions of the drug's pharmacologic actions and are manifest as nausea, vomiting, abdominal pain, and rarely hypotension and tachycardia. On the basis of current evidence, ceruletide is a safe and effective cholecystokinetic agent and small bowel and exocrine pancreatic stimulant.
 ...
PMID:Pharmacology, clinical uses, and adverse effects of ceruletide, a cholecystokinetic agent. 676 5